Physicians Realty Trust Stock Earnings Reports

Healthpeak reported solid Q1 execution and reiterated a constructive multi-asset outlook. Key corporate moves: completed the Gateway life-science acquisition in South San Francisco (buy at a discount to replacement cost) and executed a creative IPO of its senior housing platform (Janus Living) in March while retaining an ~82% stake. The Janus Living transaction crystallized a valuation gap (senior housing being valued at a much higher multiple in the private market), generated IPO proceeds and is expected to be roughly neutral to Healthpeak's 2026 earnings and accretive thereafter as proceeds are deployed. They closed an outpatient recap JV with Blackstone (6.1% cash cap on a fully occupied portfolio) and are pursuing additional recaps/acquisitions. Capital allocation actions included a $100 million buyback in April (at >10% implied FFO yield) and $200M+ of dividends paid in Q1. Operational highlights: Outpatient Medical leasing remains strong (cash re-leasing spreads ~5.4–5.8%, 91% occupancy, average escalators ~3%, low leasing costs), Lab occupancy rose to 77.7% with a pipeline that could drive at least +100 bps total occupancy vs. year-end 2025, and Senior Housing (Janus Living) delivered +35% revenue growth and +42% adjusted EBITDA in Q1. Financials and guidance: Q1 adjusted FFO $0.45; net debt/EBITDA 5.4x; raised 2026 FFO-as-adjusted guidance to $1.71–$1.75 after the buyback and transaction activity. Balance sheet actions: repaid ~$103M of secured mortgages, closed an undrawn $400M delayed-draw term loan, and have refinancing considerations (notably ~$650M senior notes maturing in June). Management emphasized disciplined, market-focused deployment of capital and continued focus on occupancy/leasing execution across the three operating segments. Risks noted: continued macro/tenant variability in life science markets and the timing of converting pipeline to occupancy; management remains selective on opportunistic life-science investments.